title: Improvement in bedtime plasma glucose level serves as a predictor of long-term blood glucose control in patients with Type 2 diabetes: a study with monotherapy of 50/50 premixed insulin analogue three times daily injection.
abstract: OBJECTIVE
  To examine which timing of blood glucose level is more important to achieve adequate blood glucose control with insulin lispro mixture-50 (Mix 50) three times daily (TID) monotherapy.
  
  
  METHODS
  The study enrolled 35 Type 2 diabetic patients. Blood glucose levels before each meal and at bedtime were measured 2 weeks after the start of the study and were analyzed in relation to improvement in hemoglobin A1c (HbA1c) at 6-8 weeks and 6 months.
  
  
  RESULTS
  HbA1c improved significantly (10.1±1.6 % at baseline, 7.8±1.1 % at 6-8 weeks and 6.8±1.1 % at 6 months). Only the blood glucose level measured at bedtime correlated with improvement in HbA1c at 6-8 weeks. For the insulin-naïve patients, only bedtime plasma glucose level also had a significant correlation with improvement in HbA1c at 6 months.
  
  
  CONCLUSIONS
  Bedtime plasma glucose level can serve as a predictor of the outcome of long-term blood glucose control during Mix 50 TID monotherapy and that bedtime plasma glucose level needs to be reduced sufficiently to achieve adequate blood glucose control.
authors.affiliation: Department of Endocrinology, Tenri Hospital, 200 Mishimacho, Tenri, Nara 632-8552, Japan. tana176k@sepia.ocn.ne.jp
authors.forename: Masami
authors.initials: M
authors.lastname: Tanaka
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ishii
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000032:analysis / Q000378:metabolism*; D002626:Chemistry, Pharmaceutical; D002940:Circadian Rhythm / Q000502:physiology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D011379:Prognosis; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D004338:Drug Combinations; D007004:Hypoglycemic Agents; D007328:Insulin